Cargando…

Simultaneous Reduction in Both HbA1c and Body Weight with Canagliflozin Versus Glimepiride in Patients with Type 2 Diabetes on Metformin

INTRODUCTION: Canagliflozin, a sodium glucose co-transporter 2 (SGLT2) inhibitor, has demonstrated sustained improvements in glycemic control and body weight reductions with treatment for up to 104 weeks in a broad range of patients with type 2 diabetes mellitus (T2DM). METHODS: This was a post hoc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Leiter, Lawrence A., Langslet, Gisle, Vijapurkar, Ujjwala, Davies, Michael J., Canovatchel, William
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2016
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4900973/ https://www.ncbi.nlm.nih.gov/pubmed/26984361 http://dx.doi.org/10.1007/s13300-016-0163-1

Ejemplares similares

A post-hoc analysis of the comparative efficacy of canagliflozin and glimepiride in the attainment of type 2 diabetes-related quality measures
por: Patel, Charmi A., et al.
Publicado: (2016)

Canagliflozin improves risk factors of metabolic syndrome in patients with type 2 diabetes mellitus and metabolic syndrome
por: Davies, Michael J, et al.
Publicado: (2017)

Efficacy and safety of canagliflozin in patients with type 2 diabetes based on history of cardiovascular disease or cardiovascular risk factors: a post hoc analysis of pooled data
por: Davies, Michael J., et al.
Publicado: (2017)

Effects of Canagliflozin on Serum Magnesium in Patients With Type 2 Diabetes Mellitus: A Post Hoc Analysis of Randomized Controlled Trials
por: Gilbert, Richard E., et al.
Publicado: (2017)

Effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on blood pressure and markers of arterial stiffness in patients with type 2 diabetes mellitus: a post hoc analysis
por: Pfeifer, Michael, et al.
Publicado: (2017)

Efficacy and Safety of Canagliflozin in Individuals Aged 75 and Older with Type 2 Diabetes Mellitus: A Pooled Analysis
por: Sinclair, Alan J., et al.
Publicado: (2016)

Measurement of HbA(1c) and HbA(2) by Capillarys 2 Flex Piercing HbA(1c) programme for simultaneous management of diabetes and screening for thalassemia
por: Ke, Peifeng, et al.
Publicado: (2017)

Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone
por: Forst, T, et al.
Publicado: (2014)

Slope of change in HbA(1c) from baseline with empagliflozin compared with sitagliptin or glimepiride in patients with type 2 diabetes
por: DeFronzo, Ralph A., et al.
Publicado: (2018)

Combination Therapy With Canagliflozin Plus Liraglutide Exerts Additive Effect on Weight Loss, but Not on HbA(1c), in Patients With Type 2 Diabetes
por: Ali, Ali Muhammed, et al.
Publicado: (2020)

Efficacy and safety of canagliflozin compared with placebo in older patients with type 2 diabetes mellitus: a pooled analysis of clinical studies
por: Sinclair, Alan, et al.
Publicado: (2014)

Deduction of the operable design space of RP-HPLC technique for the simultaneous estimation of metformin, pioglitazone, and glimepiride
por: Marie, Aya A., et al.
Publicado: (2023)

Effect of canagliflozin on serum uric acid in patients with type 2 diabetes mellitus
por: Davies, M. J., et al.
Publicado: (2015)

Dose-Ranging Effects of Canagliflozin, a Sodium-Glucose Cotransporter 2 Inhibitor, as Add-On to Metformin in Subjects With Type 2 Diabetes
por: Rosenstock, Julio, et al.
Publicado: (2012)

Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial
por: Lavalle-González, F. J., et al.
Publicado: (2013)

Canagliflozin: Effects in overweight and obese subjects without diabetes mellitus
por: Bays, Harold E, et al.
Publicado: (2014)

Development and validation of the liquid chromatographic method for simultaneous estimation of metformin, pioglitazone, and glimepiride in pharmaceutical dosage forms
por: Pandit, Vinay, et al.
Publicado: (2012)

Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial
por: Wilding, J P H, et al.
Publicado: (2013)

Comparison of Vildagliptin-Metformin and Glimepiride-Metformin Treatments in Type 2 Diabetic Patients
por: Jeon, Hyun Jeong, et al.
Publicado: (2011)

Standardization of the HbA(2) Assay
por: Paleari, Renata, et al.
Publicado: (2018)

The Anti-Breast Cancer Effect and Mechanism of Glimepiride-Metformin Adduct
por: Long, Liangyuan, et al.
Publicado: (2020)

Initiation of the SGLT2 inhibitor canagliflozin to prevent kidney and heart failure outcomes guided by HbA1c, albuminuria, and predicted risk of kidney failure
por: Tye, Sok Cin, et al.
Publicado: (2022)

The effects of early short-term insulin treatment vs. glimepiride on beta cell function in newly diagnosed type 2 diabetes with HbA1c above 9%
por: STOJANOVIC, Jelena, et al.
Publicado: (2023)

Development and Validation of Stability-Indicating RP-HPLC Method for Simultaneous Determination of Metformin HCl and Glimepiride in Fixed-Dose Combination
por: Vaingankar, Pradnya N., et al.
Publicado: (2016)

Empagliflozin treatment effects across categories of baseline HbA1c, body weight and blood pressure as an add‐on to metformin in patients with type 2 diabetes
por: Inzucchi, Silvio E., et al.
Publicado: (2020)

Associations Between Mean HbA1c, HbA1c Variability, and Both Mortality and Macrovascular Complications in Patients with Diabetes Mellitus: A Registry-Based Cohort Study
por: Tan, Joshua Kuan, et al.
Publicado: (2023)

Glimepiride and Metformin Combinations in Diabetes Comorbidities and Complications: Real-World Evidence
por: Sahay, Rakesh Kumar, et al.
Publicado: (2020)

Pharmacodynamic and pharmacokinetic interaction of losartan with glimepiride-metformin combination in rats and rabbits
por: Nagaraju, Beere, et al.
Publicado: (2021)

HbA(1c): The lower the better?
por: Araki, Eiichi, et al.
Publicado: (2011)

Canagliflozin Compared With Sitagliptin for Patients With Type 2 Diabetes Who Do Not Have Adequate Glycemic Control With Metformin Plus Sulfonylurea: A 52-week randomized trial
por: Schernthaner, Guntram, et al.
Publicado: (2013)

The True Value of HbA1c as a Predictor of Diabetic Complications: Simulations of HbA1c Variables
por: Lind, Marcus, et al.
Publicado: (2009)

Haemoglobin J-Baltimore can be detected by HbA(1c) electropherogram but with underestimated HbA(1c) value
por: Brunel, Valéry, et al.
Publicado: (2016)

Simultaneous determination of atorvastatin, metformin and glimepiride in human plasma by LC–MS/MS and its application to a human pharmacokinetic study
por: Polagani, Srinivasa Rao, et al.
Publicado: (2013)

Levels of circulating semaglutide determine reductions in HbA1c and body weight in people with type 2 diabetes
por: Overgaard, Rune V., et al.
Publicado: (2021)

Influence of Serum Albumin on HbA1c and HbA1c-Defined Glycemic Status: A Retrospective Study
por: Feng, Xiaojing, et al.
Publicado: (2021)

Stability Indicating RP-HPLC Method for the Simultaneous Determination of Atorvastatin Calcium, Metformin Hydrochloride, and Glimepiride in Bulk and Combined Tablet Dosage Form
por: Ramesh, Devi, et al.
Publicado: (2014)

Hb H Interference on Measurement Of HbA1c With Ion-Exchange HPLC
por: Agilli, Mehmet, et al.
Publicado: (2013)

Drugs affecting HbA1c levels
por: Unnikrishnan, Ranjit, et al.
Publicado: (2012)

Current Status of HbA1c Biosensors
por: Lin, Hua, et al.
Publicado: (2017)

Hemoglobin variants detected by hemoglobin A1c (HbA1c) analysis and the effects on HbA1c measurements
por: Nasir, Nadzimah Mohd, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_a3c0jkatrs4u5co7mbaohg0lcb